Related Experiment Videos
Ready-to-use pefloxacin infusion for surgical prophylaxis
R D Bapat1, J D Mohite, S K Bowalekar
1KEM Hospital, Bombay, India.
Advances in Therapy
|August 6, 1994
Summary
Peffloxacin effectively prevented postsurgical infections in a randomized trial. A single dose significantly reduced infection rates compared to placebo, with minimal side effects observed.
Area of Science:
- Infectious Diseases
- Surgical Site Infections
- Pharmacology
Background:
- Postsurgical infections pose a significant risk to patient outcomes.
- Effective prophylactic antibiotic strategies are crucial in surgical settings.
Purpose of the Study:
- To evaluate the efficacy and safety of pefloxacin for preventing postsurgical infections.
Main Methods:
- An open, comparative, randomized clinical trial involving 120 patients.
- Four groups were established: one control group and three treatment groups receiving one, two, or six doses of intravenous pefloxacin (400 mg).
Main Results:
- Peffloxacin significantly reduced postsurgical infection rates, with only 3-7% of treated patients developing infection compared to 20% in the placebo group.
- Mild side effects were reported in only two of the 90 treated patients.
Conclusions:
- Peffloxacin, administered in one to six doses, is a safe and effective option for providing antibacterial coverage during surgery.
- This prophylactic regimen substantially lowers the incidence of postsurgical infections.